Biopôle Clermont-Limagne
Technology park for life sciences
Year of creation : 2014
Statut : limited company
Size : 20
% of CA dedicated to R&D : N/A
Patents (number of) :

Contact details

Biopôle Clermont Limagne
Zone de la Varenne
Rue Henri et Gilberte Goudier
63200 Riom
France



Contact : Marc DELAUNAY
Phone : +33 546 284 567
Email : marc.delaunay@valbiotis.com
Website : www.valbiotis.com

Valbiotis

VALBIOTIS is specialized in the development of innovative nutritional solutions for preventing cardiometabolic diseases and provision of nutritional support for patients.


VALBIOTIS is specialized in the development of innovative nutritional solutions for preventing cardiometabolic diseases and provision of nutritional support for patients.

 

The worldwide surge in cardiometabolic diseases has become a major public health issue which endangers the lives of patients and jeopardizes health systems. The solutions currently available to prevent cardiometabolic diseases rely on lifestyle improvement and are barely effective in stemming this global pandemic.

 

Facing the prevention challenge, VALBIOTIS develops another approach based on products that reduce disease risk factors, to complement current recommendations. Today, preventing type 2 diabetes, NASH, (non-alcoholic steatohepatitis), obesity and dyslipidemia is the core expertise of VALBIOTIS.

 

Its innovative products are plant-based and undergo strict scientific and clinical tests in collaboration with top academic research centers. VALBIOTIS teams have strong regulatory, scientific and clinical expertise thanks to their perfect knowledge of:

  • New-generation screening techniques;
  • Complete characterization of plant matter;
  • Plants purification / fractionation processes;
  • Pre-clinical tests at various levels: molecular, cellular, tissular, in vivo;
  • Design and management of clinical trials in association with specialized partners (CROs)

This process enables VALBIOTIS to design safe, clinically effective patented products, within a short development period (approximately 6 years compared to an average of 12 years for one drug), with a much lower risk profile compared to pharmaceutical products.